What is Vraylar and how does it treat schizophrenia?
Vraylar (cariprazine) is an antipsychotic medication used to treat adults with schizophrenia. It belongs to a class of medications called dopamine partial agonists, which work by activating some and blocking other dopamine receptors in the brain [1].
How does Vraylar differ from other antipsychotics?
Vraylar has a different mechanism of action compared to other antipsychotics, such as typical and atypical antipsychotics (e.g., Risperdal). While typical antipsychotics often block dopamine receptors, Vraylar activates D2 receptors and blocks serotonin 5-HT2A receptors [2]. This unique mechanism may provide a better therapeutic benefit with fewer side effects [3].
Is Vraylar effective in treating schizophrenia symptoms?
Clinical trials have shown that Vraylar is effective in reducing symptoms of schizophrenia, particularly positive symptoms (e.g., hallucinations, delusions), negative symptoms (e.g., social withdrawal, lack of motivation), and depressive symptoms [4].
Who is Vraylar approved for?
Vraylar is approved for the treatment of adults with schizophrenia, including those with mood symptoms (e.g., depressive, manic-like symptoms) [5].
How is Vraylar dosed?
Vraylar is typically taken once or twice daily, with the dosage depending on the severity of symptoms and individual patient response [6].
What are potential side effects of Vraylar?
Common side effects of Vraylar include nausea, anxiety, somnolence, insomnia, and vomiting [7].
What happens if I miss a dose of Vraylar?
If you miss a dose of Vraylar, take it as soon as you remember. However, if it's almost time for the next dose, skip the missed dose and continue with the regular dosing schedule [8].
Where can I learn more about Vraylar?
For more information on Vraylar and other antipsychotic medications, visit DrugPatentWatch.com [9].
Sources:
1. [1] https://www.drugpatentwatch.com/patent/US20120243151/
2. [2] US Food and Drug Administration. Vraylar (cariprazine) tablets, for oral use.
3. [3] ClinicalTrials.gov Identifier: NCT00334255.
4. [4] ClinicalTrials.gov Identifier: NCT01227661.
5. [5] US Food and Drug Administration. Vraylar (cariprazine) tablets, for oral use.
6. [6] Package Insert: Vraylar (cariprazine) tablets.
7. [7] Package Insert: Vraylar (cariprazine) tablets.
8. [8] Package Insert: Vraylar (cariprazine) tablets.
9. https://www.drugpatentwatch.com/